|
|
Сonditions and diseases
AIDS/HIV ALS Alzheimer's Disease Anemia Anti-Aging Treatment Arterial Hypertension Autism Cancer Diabetes Treatment Eye Diseases Idiopathic Encephalopathy Ischemic Heart Disease Liver Diseases MD Treatment Multiple Sclerosis Treatment Parkinson Treatment Rheumatoid Arthritis SMA Ulcerative Colitis. Crohn’s Disease
News about stem cells
Stem cell treatment protects bone marrow from damaging chemotherapy effects in cancer patients
12 May
Stem cell therapy can protect cancer patients from damaging side-effects of chemotherapy, a new trial in the US suggests.
12 May
Stem cell therapy can protect cancer patients from damaging side-effects of chemotherapy, a new trial in the US suggests.
New Approach to Treating Muscular Dystrophy With Stem Cells
05 May
Scientists from the Lillehei Heart Institute (University of Minnesota) have developed a new efficient process of making muscle cells from human stem cells and for the first time ever effectively treated with these cells muscular dystrophy in a mice model.
05 May
Scientists from the Lillehei Heart Institute (University of Minnesota) have developed a new efficient process of making muscle cells from human stem cells and for the first time ever effectively treated with these cells muscular dystrophy in a mice model.
A New Brain Stem Cell Discovered
29 April
Adult brain contains stem cells, and Researchers at Lund University (Switzerland) found a new type of these cells.
All news
29 April
Adult brain contains stem cells, and Researchers at Lund University (Switzerland) found a new type of these cells.
Treatment of Cytostatic Agranulocytosis in Patients with Leukemia by Human Embryonic Liver Hemopoietic Cells
Smikodoub Alexander, Tretyak Nataliya, Snigyr Nataliya
Cell Therapy Clinic of National Medical University and Embryonic Tissue Center "EmCell"
Cytostatic agranulocytosis and concomitant infections are the often complications of intense polychemotherapy in patients with acute leukosis. Human embryonic hemopoietic cells were used in a complex treatment of cytostatic agranulocytosis in 11 patients.
Cell suspensions, prepared each from one embryo (gestation term from 6 to 12 weeks) and cryopreserved with dimethylsulfoxid, were used. The material was tested on CFU-GM, CFU-GEMM, CD34+, and underwent the viral and bacteriological control. The embryonic cell transplantations were performed intravenously drop-wise once or twice.
11 patients with cytostatic agranulocytosis were under observation. Hemopoietic cells were administered to 6 patients in order to prevent infectious complications. At the transplantation moment 5 patients had the following complications: 1 - pneumonia, 1 - sepsis, 1 - angina, mucositis, 3 patients - fever without an educed infection focus.
During 3 days after the transplantation, a positive dynamics was observed among all the patients with developed infectious complications: general state improved, intoxication syndrome reduced, body temperature normalized (temperature of the patient with sepsis lowered to subfebrile). No infectious complications were noted among the patients, who underwent cell therapy for their prevention.
Positive dynamics of peripheral blood parameters corresponded with positive dynamics of blood clinical picture. At the moment of transplantation the leukocytes number was 0.96±0.17, granulocytes number 145.46±53.84. By the 5th day after transplantation, the leukocytes number was 3.44±2.05, granulocytes number 2,035.69±1,026.98. The statistically significant rise of leukocytes number (p<0.05) was achieved by the second week after the transplantation (8–11th day).
Concomitant thrombocytopenia (50.7±11.37) was observed in 9 patients with agranulocytosis, 5 patients were observed for the hemorrhage syndrome signs such as dotty hemorrhage eruption, nasal bleedings. After the administration of hemopoietic cells positive dynamics of thrombocytes was observed. By the 7th day after transplantation thrombocytes number was 186.55+96.35, then more (p<0.05 by the 2nd week).
Hemopoietic embryonic suspensions administration enabled to reconstitute hemopoiesis of the patients, reduce the intoxication and carry on due chemotherapy.
Cell Therapy Clinic of National Medical University and Embryonic Tissue Center "EmCell"
Cytostatic agranulocytosis and concomitant infections are the often complications of intense polychemotherapy in patients with acute leukosis. Human embryonic hemopoietic cells were used in a complex treatment of cytostatic agranulocytosis in 11 patients.
Cell suspensions, prepared each from one embryo (gestation term from 6 to 12 weeks) and cryopreserved with dimethylsulfoxid, were used. The material was tested on CFU-GM, CFU-GEMM, CD34+, and underwent the viral and bacteriological control. The embryonic cell transplantations were performed intravenously drop-wise once or twice.
11 patients with cytostatic agranulocytosis were under observation. Hemopoietic cells were administered to 6 patients in order to prevent infectious complications. At the transplantation moment 5 patients had the following complications: 1 - pneumonia, 1 - sepsis, 1 - angina, mucositis, 3 patients - fever without an educed infection focus.
During 3 days after the transplantation, a positive dynamics was observed among all the patients with developed infectious complications: general state improved, intoxication syndrome reduced, body temperature normalized (temperature of the patient with sepsis lowered to subfebrile). No infectious complications were noted among the patients, who underwent cell therapy for their prevention.
Positive dynamics of peripheral blood parameters corresponded with positive dynamics of blood clinical picture. At the moment of transplantation the leukocytes number was 0.96±0.17, granulocytes number 145.46±53.84. By the 5th day after transplantation, the leukocytes number was 3.44±2.05, granulocytes number 2,035.69±1,026.98. The statistically significant rise of leukocytes number (p<0.05) was achieved by the second week after the transplantation (8–11th day).
Concomitant thrombocytopenia (50.7±11.37) was observed in 9 patients with agranulocytosis, 5 patients were observed for the hemorrhage syndrome signs such as dotty hemorrhage eruption, nasal bleedings. After the administration of hemopoietic cells positive dynamics of thrombocytes was observed. By the 7th day after transplantation thrombocytes number was 186.55+96.35, then more (p<0.05 by the 2nd week).
Hemopoietic embryonic suspensions administration enabled to reconstitute hemopoiesis of the patients, reduce the intoxication and carry on due chemotherapy.